Retirement Systems of Alabama Cuts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Retirement Systems of Alabama trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 11,305 shares of the medical research company’s stock after selling 287 shares during the quarter. Retirement Systems of Alabama’s holdings in Charles River Laboratories International were worth $2,673,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. VisionPoint Advisory Group LLC raised its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $37,000. Operose Advisors LLC purchased a new position in shares of Charles River Laboratories International in the third quarter valued at approximately $42,000. Venturi Wealth Management LLC boosted its stake in shares of Charles River Laboratories International by 74.7% in the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after acquiring an additional 112 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $62,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $236.30 on Wednesday. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The stock’s fifty day moving average is $251.61 and its two-hundred day moving average is $225.17. The company has a market capitalization of $12.17 billion, a P/E ratio of 25.66, a P/E/G ratio of 1.83 and a beta of 1.44. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. During the same period last year, the company earned $2.98 EPS. The company’s quarterly revenue was down 7.9% on a year-over-year basis. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 over the last three months. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on CRL. Robert W. Baird raised their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Argus increased their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. UBS Group boosted their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).